ESC Professional Premium Access

Natural course and effect of tafamidis treatment in real-life octogenarians with wild-type transthyretin cardiac amyloidosis: an international multi-centre analysis.

Congress Presentation

About the speaker

Doctor Philippe Debonnaire

AZ Sint Jan, Brugge (Belgium)
8 presentations
6 followers

7 more presentations in this session

Artificial intelligence to assist the echocardiographic identification of transthyretin cardiac amyloidosis

Speaker: Doctor V. Algalarrondo (Paris, FR)

Thumbnail

Increased index of microcirculatory resistance, capillary rarefaction, elevated troponin levels, and their association with transthyretin amyloidosis cardiomyopathy

Speaker: Mr Y. Suiko (Miyazaki, JP)

Thumbnail

Association of cardiac amyloidosis with cardiovascular outcomes after aortic valve replacement in patients with severe aortic stenosis: a systematic review and meta-analysis

Speaker: Doctor T. Figueira (Stony Brook, US)

Thumbnail

RV-PA uncoupling is a strong predictor of 3-year all-cause mortality in transthyretin amyloid cardiomyopathy.

Speaker: Doctor S. Schwarting (Munich, DE)

Thumbnail

Increase in serum TTR levels observed with acoramidis treatment in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): insights from ATTRibute-CM and its open-label extension

Speaker: Doctor M. Maurer (New York, US)

Thumbnail

Access the full session

Cardiac amyloidosis: diagnosis and outcomes

Speakers: Doctor P. Debonnaire, Doctor V. Algalarrondo, Mr Y. Suiko, Doctor T. Figueira, Doctor S. Schwarting...
Thumbnail

About the event

Image

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations